The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | T-DXd after HER2-TKI exposure in HER2 exon 20 insertion-positive NSCLC
Yu Tanaka, MD, PhD, National Cancer Center Hospital East, Tokyo, Japan, explores data from the LC-SCRUM-Asia study examining trastuzumab deruxtecan (T-DXd) efficacy in HER2 exon 20 insertion-positive non-small cell lung cancer (NSCLC) stratified by prior HER2 tyrosine kinase inhibitor (TKI) exposure. Response rates were attenuated following prior selective HER2-TKI therapy compared with TKI-naïve patients; however, clinically meaningful activity was retained, including in patients who had not responded to prior HER2-TKIs, supporting trastuzumab deruxtecan as a viable subsequent therapy option. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Our study addressed the clinically important sequencing in the HER2-EXON20 insertion, positive non-small cell lung cancer. These are prior HER2-TKI exposure affected the efficacy of the subsequent TDXD. These are the retrospective analysis from the National Cancer Center Hospital East and ELISION Asia. ELISION Asia is the largest genomic screening platform in lung cancer in Japan...
Our study addressed the clinically important sequencing in the HER2-EXON20 insertion, positive non-small cell lung cancer. These are prior HER2-TKI exposure affected the efficacy of the subsequent TDXD. These are the retrospective analysis from the National Cancer Center Hospital East and ELISION Asia. ELISION Asia is the largest genomic screening platform in lung cancer in Japan. We evaluated 77 patients treated with TDXD. 60 were TK naïve, 7 had previously received poziotinib or sevaletinib, and 10 patients had received non-selective HER-family TKIs, including poziotinib. The TDXD activity appeared lower after prior TK exposure. The objective response rate was 60% in TK naïve patients, 29% after poziotinib or sevaletinib, and 60% after non-selective HER to half-family TKIs. Median progression-free survival was 9.9, 6.5, and 5.3 months, respectively. However, the lack of response to prior TKI does not necessarily predict lack of the benefit from the TDXD. Among 30 patients without partial response to prior TKI, 8 achieved partial response with subsequent TDXD. So TDXD remains an important treatment option after TKI therapy. Thank you.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
